Skip to content

Covid-19 coronavirus: How the global life sciences sector is responding to the pandemic

Our life sciences sector team reviews the steps taken by the industry and public bodies to minimise disruption to regular business activities and to promote the development and supply of medicines and medical equipment for use against Covid-19. 

The team considers the key areas at the forefront of the response to Covid-19 including: R&D, clinical trials, supply chains, regulatory compliance and IP.  

This article was first published in the June 2020 edition of PLC

Recommended content